Therapeutic pCRISPRi Delivery to Lung Squamous Cell Carcinoma by Combining Nanobubbles and Ultrasound
Pharmaceutics · 13.08.2025 · 17 (8) · 1053
DOI: 10.3390/pharmaceutics17081053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 13.08.2025. Verfasst von Taiki Yamaguchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Ha…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JST SPRING, Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan, Naito Foundation.
Abstract (Originalsprache)
Background/Objectives: Lung squamous cell carcinoma (SCC), a major subtype of non-small cell lung cancer, remains a significant clinical challenge due to a scarcity of actionable molecular targets and the limited effectiveness of current targeted therapies. Emerging treatment strategies inhibit the gene expression of lineage survival oncogenes such as ΔNp63 and SOX2. CRISPR interference (CRISPRi) is a promising method to downregulate these genes; however, the efficacy depends on effective delivery. Here, we focused on the delivery system using nanobubbles (NBs) and ultrasound (US) for site-specific CRISPRi delivery to SCC. We evaluated the therapeutic efficacy of plasmid-based CRISPRi (pCRISPRi) targeting SOX2 or ΔNp63 using intratumoral pCRISPRi/NBs injections followed by US.
Methods
A mixture of NBs and pCRISPRi was injected directly into the tumors and exposed to US-induced cavitation to facilitate pCRISPRi uptake. Tumor volume was measured every other day, and apoptosis was assessed by TUNEL assay.
Results
In a lung SCC xenograft model, NBs/US-mediated pCRISPRi delivery induced apoptosis and significantly suppressed tumor growth.
Conclusions
These findings suggest that US-guided, NB-facilitated delivery of pCRISPRi can locally suppress lineage survival oncogenes and trigger tumor cell death, representing a promising targeted therapy for lung SCC. Additionally, this platform could be adapted to other cancers by targeting alternative factors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji 192-0392, Tokyo, Japan.
- Laboratory of Genome Editing Breeding, Graduate School of Agriculture, Kyoto University, 448-5 Kajiicho, Kamigyo-ku, Kyoto-shi 602-0841, Kyoto, Japan.
- Genome Editing Innovation Center, Hiroshima University, 3-10-23 Kagamiyama, Higashi-Hiroshima 739-0046, Hiroshima, Japan.
- Department of General Surgery, Kawasaki Medical School, 2-6-1 Nalasange, Kita-ku, Okayama 700-8505, Okayama, Japan.
ORCID-Profile: Taiki Yamaguchi, Yoko Endo-Takahashi, Tetsushi Sakuma
Förderung
- JST SPRING
- Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan
- Naito Foundation
Zitieren
APA
Yamaguchi, T., Endo-Takahashi, Y., Amano, T., Ihara, A., Sakuma, T., Yamamoto, T., Fukazawa, T., & Negishi, Y. (2025). Therapeutic pCRISPRi Delivery to Lung Squamous Cell Carcinoma by Combining Nanobubbles and Ultrasound. Pharmaceutics, 17(8), 1053. https://doi.org/10.3390/pharmaceutics17081053
Vancouver
Yamaguchi T, Endo-Takahashi Y, Amano T, Ihara A, Sakuma T, Yamamoto T, et al. Therapeutic pCRISPRi Delivery to Lung Squamous Cell Carcinoma by Combining Nanobubbles and Ultrasound. Pharmaceutics. 2025;17(8):1053. doi:10.3390/pharmaceutics17081053
BibTeX
@article{Yamaguchi2025,
author = {Yamaguchi, Taiki and Endo-Takahashi, Yoko and Amano, Takumi and Ihara, Arina and Sakuma, Tetsushi and Yamamoto, Takashi and Fukazawa, Takuya and Negishi, Yoichi},
title = {Therapeutic pCRISPRi Delivery to Lung Squamous Cell Carcinoma by Combining Nanobubbles and Ultrasound},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {8},
pages = {1053},
doi = {10.3390/pharmaceutics17081053}
}
EUVIMED